Navegando por Palavras-chave "CLINICAL TRIALS"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Assessing the cost effectiveness of NSAID: an international perspective
    (J Rheumatol Publ Co, 1995-07-01) Drummond, M.; Ferraz, M. B.; Mason, J.; Universidade Federal de São Paulo (UNIFESP); MCMASTER UNIV
    A number of factors may affect the cost effectiveness of treatments and can cause this to vary by location. These factors include the patient population, relative price levels, clinical practice patterns and incentives to health professionals and institutions such as hospitals. This paper illustrates these issues by assessing the relative cost effectiveness of 3 nonsteroidal antiinflammatory drugs (NSAID), with different levels of gastrointestinal side effects, in 3 countries. We conclude that the relative cost effectiveness of drugs is not only dependent on drug price but may also vary by country.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Combination Therapy with Methotrexate and Chloroquine in Rheumatoid Arthritis: A Multicenter Randomized Placebo-controlled Trial
    (Scandinavian University Press, 1994-01-01) Ferraz, Marcos Bosi [UNIFESP]; Pinheiro, Geraldo da Rocha Castelar [UNIFESP]; Helfenstein Junior, Milton[UNIFESP]; Albuquerque, E.; Rezende, C.; Roimicher, Luis; Brandao, Leticia de Campos [UNIFESP]; Silva, S. C.; Pinheiro, Geraldo da Rocha Castelar; Atra, Edgard [UNIFESP]; HOSP HELIOPOLIS; Universidade Federal do Rio de Janeiro (UFRJ); INAMPS; HOSP BONSUCESSO; Universidade Federal de São Paulo (UNIFESP)
    To compare the efficacy of the combination therapy Methotrexate (MTX) and Chloroquine (CHLO) with MTX and Placebo (PLA) in the treatment of Rheumatoid Arthritis.A total of 82 patients with Rheumatoid Arthritis (RA), diagnosed according to the American College of Rheumatology criteria, received orally either MTX 7.5 mg/week and CHLO 250 mg/day or MTX 7.5 mg/week and PLA 1 tablet/day. Adverse effects (AE) were monitored monthly and disease activity was assessed at 0, 2, 4 and 6 months.Sixty-eight patients completed the study. All outcome measures improved significantly in both treatment groups. Patients receiving MTX/CHLO ended the study with a significantly lower joint count, greater grip strength and better functional ability the patients in the MTX/PLA group, respectively; 4.5 vs 7.5 (P<0.05), 113.3 vs 89.1 (P<0.05) and 0.636 vs 0.811 (P<0.05). Mild AE were more frequently observed in the MTX/CHLO, 17 events in 15 patients, compared to 9 events in 8 patients in the MTX/PLA group (NS).These data indicate that MTX/CHLO is slightly more efficacious and toxic than is MTX/PLA in the treatment of RA.